Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 348 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Alzheimer's Dementia (AD) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants

NCT05686980
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-552
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Anaheim, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 21, 2026, 5:46 PM EDT
Withdrawn Phase 2Phase 3 Interventional

AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)

NCT01211782
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
caprylic triglyceride, long-chain triglyceride
Drug
Lead sponsor
Cerecin
Industry
Eligibility
55 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Oct 21, 2026, 5:46 PM EDT
Completed Phase 3 Interventional

Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)

NCT00056524
View directory record Official record
Conditions
Alzheimer's Disease, Stroke, Parkinson's Disease, Traumatic Brain Injury
Interventions
AVP-923
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
39
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 21, 2026, 5:46 PM EDT
Recruiting Not applicable Interventional

Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study

NCT02740634
View directory record Official record
Conditions
Atypical Alzheimer's Disease, Logopenic Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA), Alzheimer Disease, Alzheimer Disease, Early Onset, Amnestic Disorder, Amnestic Symptoms, Amnestic Mild Cognitive Disorder
Interventions
F-18 AV 1451, C-11 PiB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 21, 2026, 5:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Relational Research Recruitment and Engagement Intervention for Cognitive Aging Research

NCT05444244
View directory record Official record
Conditions
Dementia, Cognitive Dysfunction, Alzheimer Disease, Lewy Body Disease, Frontotemporal Dementia
Interventions
Relational Research Recruitment and Engagement Intervention
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 21, 2026, 5:46 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Online Caregiver Psychoeducation and Support for Alzheimer's

NCT00416078
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
caregiver website support, caregiver brief supportive phone calls
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 95 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 21, 2026, 5:46 PM EDT
Not listed Phase 2 Interventional

Systemic and Central Inflammation in AD

NCT06384378
View directory record Official record
Conditions
Alzheimer Disease
Interventions
11C-ER176
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
50 Years to 86 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 21, 2026, 5:46 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

NCT01466088
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Donepezil, AZD3480
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Phoenix, Arizona • Brooksville, Florida • Hallandale, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 21, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease

NCT03518073
View directory record Official record
Conditions
Alzheimer Disease (AD)
Interventions
Zagotenemab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
49
States / cities
Phoenix, Arizona • Tucson, Arizona • Encino, California + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 21, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor

NCT00940589
View directory record Official record
Conditions
Alzheimer's Disease, Sleep Disorder
Interventions
Circadin, Placebo
Drug
Lead sponsor
Neurim Pharmaceuticals Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Brooksville, Florida • St. Petersburg, Florida • Mount Arlington, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 21, 2026, 5:46 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC

NCT01268020
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[18F]-FMH3
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 21, 2026, 5:46 PM EDT
Terminated No phase listed Observational

Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial

NCT02781220
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia, Alzheimer's Disease
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
65 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 21, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease

NCT03319810
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Octagam 10%
Biological
Lead sponsor
Sutter Health
Other
Eligibility
50 Years to 84 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 21, 2026, 5:46 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

NCT06585787
View directory record Official record
Conditions
Alzheimer Disease
Interventions
KarXT, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
55 Years to 90 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
102
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 21, 2026, 5:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD

NCT03389698
View directory record Official record
Conditions
Alzheimer Disease
Interventions
GRASP Dynamic Contrast-Enhanced (DCE) MRI, 3T Brain Scan, Gadolinium-based Contrast Agent (GBCA) for MRI
Device · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
20 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 21, 2026, 5:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)

NCT03720548
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY3372993, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
11
States / cities
Long Beach, California • Daytona Beach, Florida • DeLand, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 21, 2026, 5:46 PM EDT
Terminated Phase 2 Interventional

To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

NCT04311515
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Tau Positron emission tomography (PET), Fluorodeoxyglucose (FDG) Positron emission tomography (PET), Cerebrospinal fluid (CSF) Biomarkers, Blood Biomarkers, Rating Scales, PU-AD, Placebo
Radiation · Diagnostic Test · Behavioral + 1 more
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Boca Raton, Florida • Delray Beach, Florida • Lake Worth, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 21, 2026, 5:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants

NCT04451408
View directory record Official record
Conditions
Alzheimer Disease, Healthy
Interventions
LY3372993, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
10
States / cities
Cypress, California • Long Beach, California • DeLand, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 21, 2026, 5:46 PM EDT
Recruiting Not applicable Interventional

CMN LIFU for Enhanced Glymphatic Clearance in Amyloid-Positive MCI

NCT07866768
View directory record Official record
Conditions
Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Interventions
ATTN201 Focused Ultrasound to the CMN, ATTN201 Unfocused Ultrasound
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 21, 2026, 5:46 PM EDT
Active, not recruiting Early Phase 1 Interventional

Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease

NCT03560960
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Pramlintide challenge test
Drug
Lead sponsor
Boston University
Other
Eligibility
60 Years to 90 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 21, 2026, 5:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss

NCT03587649
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease, Healthy Volunteers
Interventions
[18F]MNI-1126
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 21, 2026, 5:46 PM EDT
Completed Phase 1Phase 2 Interventional

SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

NCT04381468
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Pepinemab, Placebo
Drug
Lead sponsor
Vaccinex Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
14
States / cities
San Diego, California • Washington D.C., District of Columbia • Delray Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 21, 2026, 5:46 PM EDT
Enrolling by invitation No phase listed Observational

Expanding Access to Cognitive Health Biomarker Testing at Home

NCT07594665
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer's Dementia (AD), Subjective Cognitive Decline (SCD), Cognitive Aging
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 21, 2026, 5:46 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease

NCT06874621
View directory record Official record
Conditions
Alzheimer's Disease (AD)
Interventions
VY7523, Placebo Comparator
Drug
Lead sponsor
Voyager Therapeutics
Industry
Eligibility
50 Years to 90 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 21, 2026, 5:46 PM EDT